胆汁性肝硬変(Biliary Cirrhosis)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Biliary Cirrhosis Overview 7
Therapeutics Development 8
Pipeline Products for Biliary Cirrhosis – Overview 8
Pipeline Products for Biliary Cirrhosis – Comparative Analysis 9
Biliary Cirrhosis – Therapeutics under Development by Companies 10
Biliary Cirrhosis – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Biliary Cirrhosis – Products under Development by Companies 15
Biliary Cirrhosis – Companies Involved in Therapeutics Development 16
AlbireoPharma 16
Dr. Falk Pharma GmbH 17
GlaxoSmithKline plc 18
Intercept Pharmaceuticals, Inc. 19
Johnson & Johnson 20
MediGene AG 21
NGM Biopharmaceuticals, Inc. 22
Shire Plc 23
Virobay Inc. 24
Biliary Cirrhosis – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
A-4250 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
budesonide – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
FFP-104 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
GSK-2330672 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Leukothera – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
NGM-282 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
obeticholic acid – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
RhuDex – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
SHP-625 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ustekinumab – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
VBY-825 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Biliary Cirrhosis – Recent Pipeline Updates 51
Biliary Cirrhosis – Dormant Projects 62
Biliary Cirrhosis – Product Development Milestones 63
Featured News & Press Releases 63
Nov 08, 2014: Intercept Announces Additional Data for OCA in Primary Biliary Cirrhosis 63
May 28, 2014: Intercept Announces that FDA Grants Fast Track Designation to Obeticholic Acid for the Treatment of Patients with Primary Biliary Cirrhosis 64
Apr 12, 2014: Intercept Reports Additional Positive Data From POISE Trial at EASL Late-Breaker Session 64
Apr 11, 2014: Intercept Announces Preclinical Data Demonstrating OCA’s Potential Role in Preventing Complications of Cirrhosis 66
Apr 04, 2014: Data From Intercept’s Pivotal Phase 3 POISE Trial of Its FXR Agonist Obeticholic Acid to Treat Primary Biliary Cirrhosis and Other Key Obeticholic Acid Data to be Presented at EASL 2014 67
Mar 16, 2014: Intercept Announces Positive Pivotal Phase 3 POISE Trial Results 68
Jan 09, 2014: Intercept Provides 2013 Year-End Update and 2014 Anticipated Milestones 69
Dec 13, 2013: Medigene Granted Additional Patent for RhuDex for the Treatment of Autoimmune Diseases 71
Nov 18, 2013: Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases 72
Oct 29, 2013: Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75